Oncology Booming But Cost Outlook Grim, IMS Says
This article was originally published in PharmAsia News
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new report.
You may also be interested in...
Pricing drugs differently by indication presents an opportunity to better align the cost of medicines to value in certain cases, but the regulatory, policy and administrative challenges are daunting. Experts debated the challenges and opportunities during the ISPOR annual meeting.
Rebates have become industry’s go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.